Orthokeratinized Odontogenic Cyst of the Mandible with Heterotopic Cartilage

Cartilaginous metaplasia is a rare but well-documented phenomenon occurring in the wall of odontogenic keratocyst. The mural cartilage not associated with odontogenic keratocyst has been reported only once in a maxillary teratoid cyst of congenital origin to our knowledge. A case presented is a 38-year-old man with intraosseous keratinizing epidermoid cyst in the mandible, the wall of which contained a nodule of mature hyaline cartilage. The present lesion likely represents a previously undescribed, histologic hybrid consisting of orthokeratinized odontogenic cyst and cartilaginous heterotopia

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Background Genetic abnormalities in cell cycle control are common in malignant melanoma. UCN-01 (7-hydroxystaurosporine) is an investigational agent that exhibits antitumor activity by perturbing the cancer cell cycle. A patient with advanced melanoma experienced a partial response in a phase I trial of single agent UCN-01. We sought to determine the activity of UCN-01 against refractory metastatic melanoma in a phase II study. Patients and methods Patients with advanced melanoma received UCN-01 at 90 mg/m2 over 3 h on cycle 1, reduced to 45 mg/m2 over 3 h for subsequent cycles, every 21 days. Primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). A two-stage (17 + 16), single arm phase II design was employed. A true response rate of ≥20% (i.e., at least one responder in the first stage, or at least four responders overall) was to be considered promising for further development of UCN-01 in this setting. Results Seventeen patients were accrued in the first stage. One patient was inevaluable for response. Four (24%) patients had stable disease, and 12 (71%) had disease progression. As there were no responders in the first stage, the study was closed to further accrual. Median PFS was 1.3 months (95% CI, 1.2–3.0) while median OS was 7.3 months (95% CI, 3.4–18.4). One-year and two year OS rates were 41% and 12%, respectively. A median of two cycles were delivered (range, 1–18). Grade 3 treatment-related toxicities include hyperglycemia (N = 2), fatigue (N = 1), and diarrhea (N = 1). One patient experienced grade 4 creatinine elevation and grade 4 anemia possibly due to UCN-01. No dose modification was required as these patients had disease progression. Conclusion Although well tolerated, UCN-01 as a single agent did not have sufficient clinical activity to warrant further study in refractory melanoma

Odontogenic tumors and tumor —like lesions in Tanzania

Objectives: To retrospectively document the pattern of occurrence of odontogenic tumours in Tanzania over fifteen years. Design: The histologic types, site, age and sex distribution of odontogenic tumours in Tanzania from 1982 to 1997 were reviewed. Records of patients who presented to the four referral centres in Tanzania and who had histologically proven oral tumours and tumourlike conditions were examined. Results: Odontogenic tumours comprised about 12.2% of all oral tumours and tumour-like conditions. The majority of odontogenic tumours (55.3%) were seen in patients below 30 years of age and they more commonly affected the mandible than maxilla. Ameloblastoma was the most commonly seen odontogenic tumour (73.7%), followed by odontogenic myxoma (10.3%). The site, sex, and histologic distribution of ameloblastoma did not differ from other African studies. Over 50% of patients with ameloblastoma presented to hospital late (after three or more years). Conclusion: In order to improve on the treatment outcome, the need for early detection and referral of patients by medical personnel and dentists is stressed. (East African Medical Journal: 2002 79(1): 3-7

A 4-year prospective study on epidemiology and clinicopathological presentation of odontogenic tumors in Tanzania.

Item does not contain fulltex

Odontogenic tumours and tumour-like lesions in Tanzania.

OBJECTIVES: To retrospectively document the pattern of occurrence of odontogenic tumours in Tanzania over fifteen years. DESIGN: The histologic types, site, age and sex distribution of odontogenic tumours in Tanzania from 1982 to 1997 were reviewed. Records of patients who presented to the four referral centres in Tanzania and who had histologically proven oral tumours and tumour-like conditions were examined. RESULTS: Odontogenic tumours comprised about 12.2% of all oral tumours and tumour-like conditions. The majority of odontogenic tumours (55.3%) were seen in patients below 30 years of age and they more commonly affected the mandible than maxilla. Ameloblastoma was the most commonly seen odontogenic tumour (73.7%), followed by odontogenic myxoma (10.3%). The site, sex, and histologic distribution of ameloblastoma did not differ from other African studies. Over 50% of patients with ameloblastoma presented to hospital late (after three or more years). CONCLUSION: In order to improve on the treatment outcome, the need for early detection and referral of patients by medical personnel and dentists is stressed

Odontogenic tumours and tumour-like lesions in Tanzania.

Item does not contain fulltextOBJECTIVES: To retrospectively document the pattern of occurrence of odontogenic tumours in Tanzania over fifteen years. DESIGN: The histologic types, site, age and sex distribution of odontogenic tumours in Tanzania from 1982 to 1997 were reviewed. Records of patients who presented to the four referral centres in Tanzania and who had histologically proven oral tumours and tumour-like conditions were examined. RESULTS: Odontogenic tumours comprised about 12.2% of all oral tumours and tumour-like conditions. The majority of odontogenic tumours (55.3%) were seen in patients below 30 years of age and they more commonly affected the mandible than maxilla. Ameloblastoma was the most commonly seen odontogenic tumour (73.7%), followed by odontogenic myxoma (10.3%). The site, sex, and histologic distribution of ameloblastoma did not differ from other African studies. Over 50% of patients with ameloblastoma presented to hospital late (after three or more years). CONCLUSION: In order to improve on the treatment outcome, the need for early detection and referral of patients by medical personnel and dentists is stressed

Odontogenic myxoma: a clinicopathological study of 33 cases.

Item does not contain fulltextOdontogenic myxoma, a rare tumour that occurs in the jaws, has been reported to be the second commonest odontogenic tumour in many countries. Few studies, however, provide detailed clinicopathological findings of a large series of cases and no study so far has attempted to calculate the incidence of this condition. Retrospective and prospective studies were carried out in Tanzania from 1982 to 1998 (16 years) and 1999 to 2002 (4 years), respectively. A total of 33 cases of myxomas were found with a male:female ratio of 1:1.83. Most of the tumours were located in the mandible compared to the maxilla and were predominantly multilocular. Pain, diasthesia, ulceration, invasion of the soft tissues and tooth mobility were among the symptoms that patients presented with although the majority had no clinical signs or symptoms. Based on the prospective study only, an annual incidence of 0.07 per million can be ascertained. Late reporting was a common feature in this group of patients. Radical surgery with resection of the tumour with a safe margin is advocated